GSTO1 and colorectal cancer: CRISPR/Cas9 mediated knocking out of glutathione S-Transferase Omega 1 (GSTO1) in colorectal cancer cells enhances the cytotoxicity of chemotherapeutics, including cisplatin and oxaliplatin [71].